Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7116994 | 0.82 | LMNA (0.39) | C5AR1HSD11B1HPGDCA1CA2 | |
| SCHEMBL6286862 | 0.80 | CA2 (0.39) | CA1CA2 | |
| SCHEMBL3146701 | 0.73 | HPGD (0.42) | HPGDPTGS2 | |
| SCHEMBL6284421 | 0.68 | HPGD (0.57) | HPGDCA1CA2 | |
| SCHEMBL7011092 | 0.68 | CA12 (0.57) | CXCL8HPGDCA1CA2PTGS1 | |
| SCHEMBL6315710 | 0.68 | CA12 (0.57) | CXCL8HPGDCA1CA2PTGS1 | |
| SCHEMBL6284183 | 0.67 | HPGD (0.57) | HPGDPTGS1PTGS2 | |
| SCHEMBL27357591 | 0.63 | C5AR1 (0.52) | C5AR1HSD11B1HPGDHDAC1CES2 | |
| SCHEMBL2830034 | 0.63 | MAPT (0.61) | C5AR1HSD11B1HPGDCA1CA2 | |
| SCHEMBL17100175 | 0.63 | CES2 (0.48) | C5AR1HSD11B1HPGDHDAC1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887903-B1 | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. (IT) | 2005-05-03 | — | — | US | disclosed |
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | DOMPE S.P.A. | 2003-11-20 | — | — | US | disclosed |
| EP-1123276-B1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | DOMPE SPA (IT) | 2003-01-08 | — | — | EP | disclosed |
| EP-1123276-A1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | Dompe' S.P.A. (IT) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024710-A1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | DOMPE' S.P.A. (IT) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216392-A1 | N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them | ELANE, MPO, FPR1 | C5AR1 75/4885HSD11B1 2507/4885CXCL8 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.